CA2622558A1 - Therapie combinatoire pour une digestion controlee des glucides - Google Patents

Therapie combinatoire pour une digestion controlee des glucides Download PDF

Info

Publication number
CA2622558A1
CA2622558A1 CA002622558A CA2622558A CA2622558A1 CA 2622558 A1 CA2622558 A1 CA 2622558A1 CA 002622558 A CA002622558 A CA 002622558A CA 2622558 A CA2622558 A CA 2622558A CA 2622558 A1 CA2622558 A1 CA 2622558A1
Authority
CA
Canada
Prior art keywords
agent
pharmaceutical preparation
group
agents
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002622558A
Other languages
English (en)
Inventor
Alan Watson
Laura Brass
Bard J. Geesaman
Vaughn Kailian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elixir Pharmaceuticals Inc
Original Assignee
Elixir Pharmaceuticals, Inc.
Alan Watson
Laura Brass
Bard J. Geesaman
Vaughn Kailian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Pharmaceuticals, Inc., Alan Watson, Laura Brass, Bard J. Geesaman, Vaughn Kailian filed Critical Elixir Pharmaceuticals, Inc.
Publication of CA2622558A1 publication Critical patent/CA2622558A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002622558A 2005-09-14 2006-09-13 Therapie combinatoire pour une digestion controlee des glucides Abandoned CA2622558A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71753605P 2005-09-14 2005-09-14
US60/717,536 2005-09-14
PCT/US2006/035761 WO2007033292A2 (fr) 2005-09-14 2006-09-13 Thérapie combinatoire pour une digestion contrôlée des glucides

Publications (1)

Publication Number Publication Date
CA2622558A1 true CA2622558A1 (fr) 2007-03-22

Family

ID=37865568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002622558A Abandoned CA2622558A1 (fr) 2005-09-14 2006-09-13 Therapie combinatoire pour une digestion controlee des glucides

Country Status (4)

Country Link
EP (1) EP1931359A4 (fr)
CN (1) CN101325959A (fr)
CA (1) CA2622558A1 (fr)
WO (1) WO2007033292A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888382B2 (en) 2005-04-20 2011-02-15 Kissei Pharmaceutical Co., Ltd. Combined pharmaceutical preparation for treatment of type 2 diabetes
JP2009514896A (ja) * 2005-11-07 2009-04-09 エリクシアー ファーマシューティカルズ， インコーポレイテッド メトホルミンおよびメグリチニドの組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
US4898986A (en) * 1986-09-09 1990-02-06 Takeda Chemical Industries, Ltd. Inosose derivatives, production and use thereof
JP2008514549A (ja) * 2004-09-14 2008-05-08 エリクシアー ファーマシューティカルズ， インコーポレイテッド 制御された炭水化物消化のための併用療法
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation

Also Published As

Publication number Publication date
EP1931359A2 (fr) 2008-06-18
WO2007033292A2 (fr) 2007-03-22
WO2007033292A3 (fr) 2007-06-28
EP1931359A4 (fr) 2009-04-01
CN101325959A (zh) 2008-12-17

Similar Documents

Publication Publication Date Title
ES2302702T3 (es) Composicion farmaceutica que comprende una combinacion de metformina y glibenclamida.
JP4845740B2 (ja) 糖尿病を治療するための組成物および方法
JP6121334B2 (ja) 胃および結腸製剤ならびにそれらを作製するための方法および使用するための方法
ES2150889T3 (es) Combinacion de glibenclamida-metformina para el tratamiento de la diabetes mellitus tipo ii.
US20060193845A1 (en) Combination therapy for controlled carbohydrate digestion
WO2002004024A1 (fr) Composition destinee au traitement du diabete
RU2201272C2 (ru) Применение ингибиторов желудочно-кишечной липазы
KR20080080220A (ko) Ｄｐｉｖ 억제제 및 메트포르민 또는 티아졸리딘디온을병용한 2형 당뇨병의 치료
Riddle Oral pharmacologic management of type 2 diabetes
US6916796B2 (en) Use of pullulan as a slowly digested carbohydrate
PT1011673E (pt) Nova posologia para a dmni
KR20080028415A (ko) ＰＰＡＲγ 애고니스트를 함유하는 의약 조성물
Schlesinger Methemoglobinemia and anemia in a dog with acetaminophen toxicity.
CA2132427A1 (fr) Methode et composition pour supprimer les effets secondaires des medicaments anti-inflammatoires
CA2622558A1 (fr) Therapie combinatoire pour une digestion controlee des glucides
Chan et al. Short bowel syndrome in adults—part 4-A. A guide to front line drugs used in the treatment of short bowel syndrome
AU776376B2 (en) Remedies for hyperammonemia
Hebuterne et al. Correction of malnutrition following gastrectomy with cyclic enteral nutrition
Reasner et al. Treatment of type 2 diabetes mellitus: a rational approach based on its pathophysiology
CN104582701A (zh) 减轻体重的方法
WO2010093243A1 (fr) Utilisation d'une combinaison de diazoxyde et de metformine pour le traitement de l'obésité ou des troubles liés à l'obésité
US6683098B1 (en) Use of drug miglitol (Glyset) for treatment of obesity to prevent weight gain for losing weight and for weight control
Hoffer Negative and positive side effects of vitamin B3
Thanikachalam Review on Comparison of Diabetic Drugs
Greenway Hydrogels in the Treatment of Obesity

Legal Events

Date Code Title Description
FZDE Dead